BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 37011878)

  • 1. Cuproptosis illustrates tumor micro-environment features and predicts prostate cancer therapeutic sensitivity and prognosis.
    Cheng B; Tang C; Xie J; Zhou Q; Luo T; Wang Q; Huang H
    Life Sci; 2023 Jul; 325():121659. PubMed ID: 37011878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cuproptosis Regulates Microenvironment and Affects Prognosis in Prostate Cancer.
    Li C; Xiao Y; Cao H; Chen Y; Li S; Yin F
    Biol Trace Elem Res; 2024 Jan; 202(1):99-110. PubMed ID: 37155084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma.
    Yan C; Niu Y; Ma L; Tian L; Ma J
    J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel cuproptosis-related subtypes and gene signature associates with immunophenotype and predicts prognosis accurately in neuroblastoma.
    Tian XM; Xiang B; Yu YH; Li Q; Zhang ZX; Zhanghuang C; Jin LM; Wang JK; Mi T; Chen ML; Liu F; Wei GH
    Front Immunol; 2022; 13():999849. PubMed ID: 36211401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The signature of cuproptosis-related immune genes predicts the tumor microenvironment and prognosis of prostate adenocarcinoma.
    Yao K; Zhang R; Li L; Liu M; Feng S; Yan H; Zhang Z; Xie D
    Front Immunol; 2023; 14():1181370. PubMed ID: 37600770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
    Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
    Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of cuproptosis -related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in prostate cancer.
    Jin L; Mei W; Liu X; Sun X; Xin S; Zhou Z; Zhang J; Zhang B; Chen P; Cai M; Ye L
    Front Immunol; 2022; 13():974034. PubMed ID: 36203594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
    Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel molecular subtypes and a signature to predict prognosis and therapeutic response based on cuproptosis-related genes in prostate cancer.
    Zhang J; Jiang S; Gu D; Zhang W; Shen X; Qu M; Yang C; Wang Y; Gao X
    Front Oncol; 2023; 13():1162653. PubMed ID: 37205181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of cuproptosis-related genes for predicting the development of prostate cancer.
    Wang X; Chen X; Xu C; Zhou W; Wu D
    Open Med (Wars); 2023; 18(1):20230717. PubMed ID: 37711156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
    Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
    BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
    Chen X; Hu G; Xiong L; Xu Q
    Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
    [No Abstract]   [Full Text] [Related]  

  • 13. Construction of cuproptosis-related gene signature to predict the prognosis and immunotherapy efficacy of patients with bladder cancer through bioinformatics analysis and experimental validation.
    Liu Z; Zhu F; Zhang P; Qian B; Liu W; Xiao Y; Chen N; He Q; Xiao J
    Front Genet; 2022; 13():1074981. PubMed ID: 36506302
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.
    Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP
    Front Immunol; 2022; 13():933973. PubMed ID: 36045691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of cuproptosis identified immune microenvironment and prognosis in acute myeloid leukemia.
    Luo D; Liu S; Luo J; Chen H; He Z; Gao Z; Wen Z; Liu X; Xu N
    Clin Transl Oncol; 2023 Aug; 25(8):2393-2407. PubMed ID: 36826709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of cuproptosis-related genes and tumor microenvironment infiltration characterization in breast cancer.
    Song S; Zhang M; Xie P; Wang S; Wang Y
    Front Immunol; 2022; 13():978909. PubMed ID: 36341328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cuproptosis-related LncRNA signature: Integrated analysis associated with biochemical recurrence and immune landscape in prostate cancer.
    Ren L; Yang X; Wang W; Lin H; Huang G; Liu Z; Pan J; Mao X
    Front Genet; 2023; 14():1096783. PubMed ID: 36911392
    [No Abstract]   [Full Text] [Related]  

  • 20. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma.
    Chen Y; Tang L; Huang W; Zhang Y; Abisola FH; Li L
    Front Endocrinol (Lausanne); 2022; 13():963220. PubMed ID: 36353226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.